Third, among rituximab-treated MPA patients, patients belonging to a lower MPO-ANCA titre group exhibited a higher risk for ESKD progression than those belonging to a higher MPO-ANCA titre group. This evidence concerns the gene MPO and microscopic polyangiitis.